12-14-2011

Pegylated phthalocyanines: Synthesis and spectroscopic properties

Hairong Li
Louisiana State University

Frank R. Fronczek
Louisiana State University

M. Graa H. Vicente
Louisiana State University

Follow this and additional works at: https://digitalcommons.lsu.edu/chemistry_pubs

Recommended Citation

Li, H., Fronczek, F., & Vicente, M. (2011). Pegylated phthalocyanines: Synthesis and spectroscopic properties. *Tetrahedron Letters*, 52 (50), 6675-6678. <https://doi.org/10.1016/j.tetlet.2011.10.002>

This Article is brought to you for free and open access by the Department of Chemistry at LSU Digital Commons. It has been accepted for inclusion in Faculty Publications by an authorized administrator of LSU Digital Commons. For more information, please contact ir@lsu.edu.

Published in final edited form as:

Tetrahedron Lett. 2011 December 14; 52(50): 6675–6678. doi:10.1016/j.tetlet.2011.10.002.

Pegylated Phthalocyanines: Synthesis and Spectroscopic Properties

Hairong Li, Frank R. Fronczek, and M. Graça H. Vicente¹

Department of Chemistry, Louisiana State University, Baton Rouge, LA 70803, USA

Abstract

The syntheses and spectroscopic properties of a series of pegylated zinc(II)-phthalocyanines (Zn-Pcs) containing one, two or eight tri(ethylene glycol) chains are described. The single molecular structure of a phthalonitrile precursor containing one hydroxyl and one PEG group, and its unique intermolecular hydrogen bonding are presented. The pegylated Pcs are highly soluble in polar organic solvents and have fluorescence quantum yields in the range 0.08–0.28.

Keywords

PDT; PEG; phthalocyanine; phthalonitrile; fluorescence

Phthalocyanines (Pcs) are unique tetrapyrrolic macrocycles containing an extended aromatic 18- π electron system. Among the various applications of modified Pcs, they are promising photosensitizers for photodynamic therapy (PDT) of cancer^{1,2} because of their intense absorptions at long wavelengths (> 670 nm) and extraordinary ability for producing singlet oxygen. However, due to Pcs' intrinsic property of insolubility and high tendency for aggregation in aqueous solutions, research has centered on the synthesis of soluble Pcs and the tuning of their photophysical properties.^{3,4} A general approach consists of attaching multiple hydrophilic or amphiphilic substituents to the periphery or the core of Pcs, such as carboxylates,⁵ sulfonates,⁶ phosphonates,⁷ pyridinium ions,⁸ hydroxyl groups,⁹ peptides,¹⁰ oligonucleotides,¹¹ and polyethylene glycol (PEG)¹² groups. In particular, the use of PEG as effective carriers^{13–15} or covalently attached for drug delivery to target tissues,^{16,17} is well documented. PEG-functionalized photosensitizers generally show improved serum life, reduced uptake by the reticuloendothelial system, enhanced cellular permeability and increased tumor accumulation.¹⁸ Lutetium texaphyrin or Lutex[®], containing two short PEG chains and two free hydroxyl groups, has demonstrated high photodynamic efficiency and has been evaluated in phase I/II clinical trials.^{19,20} Recently, several groups^{21–25,35,36} and us^{8,26} reported the synthesis of PEG-substituted photosensitizers (porphyrins, chlorins and Pcs) for application in PDT. Although such molecules generally show improved solubilities, their photophysical and biological properties depend on the length and number of PEG chains at the macrocycle periphery; two to four low weight PEGs (< 2000 amu) tend to minimize compound aggregation and improve tumor cellular uptake. Herein, we report the synthesis and photophysical properties of a new series of PEG-substituted zinc(II)-Pcs containing one, two or eight tri(ethylene glycol) chains, which are highly soluble in polar

© 2011 Elsevier Ltd. All rights reserved.

^{*}Corresponding author. Tel.: +1-225-578-7405; fax: +1-225-578-3458; vicente@lsu.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

organic solvents. Furthermore, the new pegylated Zn-Pcs are pure compounds, rather than statistical mixtures of regioisomers, as previously reported.^{21,36}

The synthetic route to tri(ethylene glycol) conjugated Pc **4–6** are shown in Scheme 1. Mono-, di- and octa-tri(ethylene glycol) substituted Zn-Pcs **4–6** were obtained from the corresponding phthalonitrile precursors **1–3**. Phthalonitrile **1** was synthesized from 4,5-bis(2,5-di-*tert*-butyl-4-hydroxyphenoxy)phthalonitrile⁹ and 2.3 equiv. of 2-[2-(2-iodoethoxy)ethoxy]ethanol at 50 °C, in the presence of potassium carbonate, in 59% yield.²⁷ 2-[2-(2-Iodoethoxy)ethoxy]ethanol was synthesized from commercially available 2-[2-(2-chloroethoxy)ethoxy] ethanol and sodium iodide, by refluxing in acetone for 24 h, in 90% yield. Pc **4** containing two PEG chains terminated with hydroxyl groups (PEGOH) was synthesized by a mixed macrocyclization using zinc(II) as template in the presence of excess of unsubstituted phthalonitrile. The reaction was heated to 140 °C and catalyzed by DBU to afford Pc **4** as a dark green solid in 8% yield.²⁸

Several examples of α -substituted Pcs have been previously reported.^{12,24,29–32} Such compounds are often observed to absorb and emit at longer wavelengths compared with their β -substituted analogs. This property could favor their application as photosensitizers for PDT due to the deeper penetration of long wavelength light into most human tissues. Furthermore, α -substituted Pcs in general show higher solubility in polar organic solvents and lower aggregation tendency than the correspondig β -substituted Pcs. The α -substituted octa-PEG-Pc **5**³³ containing eight PEGOMe chains at the α positions of the Pc macrocycle, was synthesized from phthalonitrile **2** using a lithium template, followed by anhydrous zinc(II) acetate.²⁸ The precursor phthalonitrile **2** was synthesized by di-pegylation of 2,6-dihydroxyphthalonitrile using 1.2 equiv. $\text{CH}_3(\text{OCH}_2\text{CH}_2)_3\text{I}$ ⁸ by activation with 2 equiv. potassium carbonate in 90% yield.²⁷ The synthesis of Pc **6** containing one hydroxyl group and one PEGOMe group at the α positions of the Pc was accomplished by mixed condensation of phthalonitrile **3** and unsubstituted phthalonitrile, similar to the method used for the synthesis of Pc **4**.²⁸ Phthalonitrile **3** was prepared by mono-pegylation of commercially available 2,6-dihydroxyphthalonitrile using 1 equiv. $\text{CH}_3(\text{OCH}_2\text{CH}_2)_3\text{I}$ ⁸ in DMF at room temperature, in 43% yield.²⁷ The structures of the two independent molecules of phthalonitrile **3** in the crystal are shown in Figure 1. They are very similar in conformation, except for the central ethylene glycol group. In both structures, the magnitude of the torsion angle about the C-C bond is the same, but opposite in sign, +65.5 and -65.9°. However, the torsion angles about the neighboring C-O bonds are such that the overall shape of the molecule does not change significantly. Torsion angles about those C-O bonds are -176.8° and +172.5° in the one molecule and -84.2 and -84.9° in the other molecule. Each of the independent molecules forms an intermolecular hydrogen-bonded dimer about an inversion center, as shown in Figure 1. The acceptors are ether O, the O...O distances are 2.621(2) and 2.655(2) Å, and each dimer is a 26-membered ring.³⁴

The PEG-substituted Pcs **4–6** are soluble in polar organic solvents, including DMF, DMSO, acetonitrile and THF, as well as in less polar solvents such as dichloromethane and diethyl ether. The structures of these targeted Pcs were confirmed by NMR and MS spectroscopies. The ¹H NMR of Pc **4** in deuterated DMF shows the characteristic aromatic protons above 7 ppm, as we have previously reported.^{9,31,32} Three sets of aromatic peaks at 9.45, 9.25 and 8.95 ppm in the downfield region were observed and assigned to the α -protons of this A₃B-type Pc: 9.45 ppm (broad, 4H) for the α -protons at the two symmetrical isoindole subunits (A' A'); 9.22 ppm (doublet, 2H) for the α -protons at the third isoindole subunit (A) and 8.95 ppm (singlet, 2H) for the α -protons at the substituted isoindole subunit (B). The signals in the range of 8.21–8.17 ppm (multiplet, 6H) are due to the β -ring protons in the “A” part. The relative upfield protons at 7.31 (singlet, 2H) and 7.25 (singlet, 2H) ppm are due to the β -substituted phenyl rings. The aliphatic proton signals in the PEG chain appear between

3.56–4.38 ppm, and the OH signals overlap with the solvent peak at around 3.5 ppm. Another two singlet peaks at 1.59 (18H) and 1.40 (18H) are assigned to the *tert*-butyl groups on the substituted phenyl rings. The symmetrical octa-pegylated Zn-Pc **5** has a simpler aromatic proton pattern due to the symmetry of the β -ring protons, appearing at 7.76 ppm (doublet, 8H). The aliphatic proton signals are in the range of 3.16–4.97 ppm. Pc **4** and **5** showed single or double molecular ion modes, respectively, at m/z 1281.5361 (Pc **4**) and 965.9939 (Pc **5**) with electrospray ionization method. Pc **6** containing one hydroxyl group and one PEGOMe group at the 1,4- α -positions showed a molecular fragment ion at m/z 723.6 $[M-OCH_3]^+$ in MALDI-MS.

The absorption spectrum of Pc **4** containing two PEGOH moieties in DMSO shows a characteristic strong Q band at 677 nm (Figure 2) that strictly follows the Lambert-Beer law. This result indicates that Pc **4** exists in the monomeric form in DMSO. In acetone, Pc **4**'s Q band absorption is blue-shifted to 669 nm. Its fluorescence emission spectrum shows a peak at 680 nm in DMSO. The observed absorption and emission properties of Pc **4** are almost identical to those of 2,3-di-(2,5-di-*tert*-butyl-4-hydroxyphenoxy)-zinc(II)-phthalocyanine, previously reported by us.⁹ This result indicates that the attachment of the PEGOH moieties at the phenoxy groups doesn't significantly change the photophysical properties of the Pc's conjugated core system, which is also in agreement with reports by others.^{24,37,38} However, the fluorescence quantum yield of Pc **4** was found to be 0.28 (Table 1), which is higher than that reported for 2,3-di-(2,5-di-*tert*-butyl-4-hydroxyphenoxy)-zinc (II)-phthalocyanine (0.20).⁹ This is probably due to the conjugation of the PEGOH chains, which make the disubstituted Pc **4** more soluble and consequently forming monomeric species in DMSO. Interestingly, the OH group at the end of the PEG chain does not make the intermolecular hydrogen bonding a problem in this case. On the other hand, Pc **5** bearing eight PEGOMe groups has a significantly red-shifted Q band to the near-infrared (NIR) region at ~750 nm (Figure 2). This phenomena is due to the attachment of the eight PEGOMe groups at the Pc's α positions, which reduces the Pc's HOMO-LUMO gap and causes longer absorption wavelength compared with unsubstituted Zn(II)Pc (about 670 nm).³⁹ The observed absorption of octa- α -substituted Pc **5** is consistent with that reported for octa- α -alkyl-substituted zinc(II)-Pc.^{40,41} Pc **5** has a weak emission peak at around 751 nm and lower fluorescence quantum yield (Table 1); 0.08 is similar to the quantum yields reported for a series of cationic octa-PEG-alkylated-Zn(II)-Pcs (0.04–0.08).⁸ Pc **6** containing one hydroxyl group and one PEGOMe chain has an absorption peak at 676 nm and a broad emission peak at 677 nm. Its fluorescence quantum yield is 0.13, probably as a result of intermolecular hydrogen bonding, as already observed in phthalonitrile **3** (Figure 1). All of the Pcs **4–6** have small Stokes Shift of 1–3 nm.

In summary, we have successfully synthesized three pegylated zinc(II) Pcs **4–6** in 1–8% yields. All these PEG-Pcs are highly soluble in polar organic solvents such as acetone, DMF and DMSO. Pc **4** containing two PEGOH chains at the *para*-position of β -substituted phenoxy ring has similar absorption and emission peaks to the reported 2,3-di-(2,5-di-*tert*-butyl-4-hydroxyphenoxy)-zinc(II) Pc,⁹ but significantly higher fluorescence quantum yield (0.28), probably due to its higher solubility in DMSO. Pc **5** containing eight PEGOMe chains at the α positions shows pronounced red-shifted absorption and emission to ~750 nm. While Pc **5** has the lowest fluorescence quantum yield (0.08), Pc **6** bearing only one PEGOMe and one hydroxyl group shows similar absorption and emission wavenights to Pc **4**, but significantly lower fluorescence quantum yield (0.13), probably due to intermolecular hydrogen bonding.

Acknowledgments

The work described herein was partially supported by the National Institutes of Health, grant number R21 CA139385.

References

1. Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, Moan J, Peng Q. *J. Natl. Cancer Inst.* 1998; 90:889–905. [PubMed: 9637138]
2. Pandey, RK.; Zheng, G. *The Porphyrin Handbook*. Kadish, KM.; Smith, KM.; Guillard, R., editors. Vol. 6. Boston: Academic Press; 2000. p. 157-230.
3. Din, D.; Hanack, M. *The Porphyrin Handbook*. Kadish, KM.; Smith, KM.; Guillard, R., editors. Vol. 17. Boston: Academic Press; 2003. p. 1-36.
4. Dumoulin F, Durmus M, Ahsen V, Nyokong T. *Coord. Chem. Rev.* 2010; 254:2792–2284.
5. Liu W, Jensen TJ, Fronczek FR, Hammer RP, Smith KM, Vicente MGH. *J. Med. Chem.* 2005; 48:1033–1041. [PubMed: 15715471]
6. Yang YC, Ward JR, Seiders RP. *Inorg. Chem.* 1985; 24:1765–1769.
7. Sharman WM, Kudrevich SV, van Lier JE. *Tetrahedron Lett.* 1996; 37:5831–5834.
8. Li H, Fronczek FR, Vicente MGH. *J. Med. Chem.* 2008; 51:502–511. [PubMed: 18189349]
9. Li H, Nguyen N, Fronczek FR, Vicente MGH. *Tetrahedron.* 2009; 65:3357–3363.
10. Sibrian-Vazquez M, Ortiz J, Nesterova IV, Fernandez-Lazaro F, Sastre-Santos A, Soper SA, Vicente MGH. *Bioconjugate Chemistry.* 2007; 18:410–420. [PubMed: 17279788]
11. Nesterova IV, Verdree VT, Pakhomov S, Strickler KL, Allen MW, Hammer RP, Soper SA. *Bioconjugate Chemistry.* 2007; 18:2159–2168. [PubMed: 18030995]
12. Durmus M, Ayhan MM, Gürek AG, Ahsen V. *Dyes Pigments.* 2008; 77:570–577.
13. Gusens A, Derycke A, Missiaen L, De Vos D, Huwyler J, Eberle A, de Witte P. *Int. J. Cancer.* 2002; 101:78–85. [PubMed: 12209592]
14. Kojima C, Toi Y, Harada A, Kono K. *Bioconjugate Chemistry.* 2007; 18:663–670. [PubMed: 17375896]
15. Sawant RR, Sawant RM, Torchilin VP. *Eur. J. Phar. Biophar.* 2008; 70:51–57.
16. Zalipsky S. *Adv. Drug Delivery Rev.* 1995; 16:157–182.
17. Greenwald RB, Choe YH, McGuire J, Conover CD. *Adv. Drug Delivery Rev.* 2003; 55:217–250.
18. Hamblin MR, Miller JL, Rizvi I, Loew HG, Hasan T. *Br. J. Cancer.* 2003; 89:937–943. [PubMed: 12942129]
19. Zhu TC, Finlay JC, Hahn SM. *J. Photochem. Photobiol. B: Biol.* 2005; 79:231–241.
20. Verigos K, Stripp DCH, Mick R, Zhu TC, Whittington R, Smith D, Dimofte A, Finlay J, Busch TM, Tochner ZA, Malkowicz SB, Glatstein E, Hahn SM. *J. Environmental Pathology Toxicology and Oncology.* 2006; 25:373–387.
21. Kralova J, Briza T, Moserova I, Dolensky B, Vasek P, Pouckova P, Kejik Z, Kaplanek R, Martasek P, Dvorak M, Kral V. *J. Med. Chem.* 2008; 51:5964–5973. [PubMed: 18788727]
22. Erdem SS, Nesterova IV, Soper SA, Hammer RP. *J. Org. Chem.* 2008; 73:5003–5007. [PubMed: 18510363]
23. Zeug A, Meyer M, Lo PC, Ng DKP, Roder B. *J. Porphyrins Phthalocyanines.* 2005; 9:298–302.
24. Liu JY, Jiang XJ, Fong WP, Ng DKP. *Org. Biomol. Chem.* 2008; 6:4560–4566. [PubMed: 19039364]
25. Balaz M, Collins HA, Dahlstedt E, Anderson HL. *Org. Biomol. Chem.* 2009; 7:874–888. [PubMed: 19225670]
26. Sibrian-Vazquez M, Jensen TJ, Vicente MGH. *J. Photochem. Photobiol. B: Biol.* 2007; 86:9–21.
27. Selected spectroscopic data for phthalonitriles: **1**, ¹H NMR (acetone-d₆, 250 MHz): δ 7.32 (s, 2H, Ar-H), 7.06 (s, 2H, Ar-H), 6.91 (s, 2H, Ar-H), 4.23 (t, *J* = 4.4 Hz, 4H, OCH₂), 3.92 (t, *J* = 4.4 Hz, 4H, OCH₂), 3.70-3.51 (m, 18H, OCH₂, OH overlap), 1.37 (s, 18H, C(CH₃)₃), 1.35 (s, 18H, C(CH₃)₃). ¹³C NMR (acetone-d₆, 63 MHz): δ 155.7, 153.5, 146.3, 140.3, 138.5, 122.0, 120.6, 116.1, 112.7, 110.2 (Ar-C, CN), 73.4, 71.2, 71.1, 70.5, 68.5, 61.9 (CH₂O), 35.2, 35.1, 30.6, 29.9

- (C(CH₃)₃). HRMS-ESI: m/z 833.4947 [M+H]⁺, calcd. for [C₄₈H₆₉N₂O₁₀]⁺ 833.4946. **2**, ¹H NMR (CDCl₃, 250 MHz): δ 7.18 (s, 2H, Ar-H), 4.12 (t, J = 4.6 Hz, 4H, OCH₂), 3.76 (t, J = 4.6 Hz, 4H, OCH₂), 3.63–3.59 (m, 4H, OCH₂), 3.54–3.49 (m, 8H, OCH₂), 3.43–3.39 (m, 4H, OCH₂), 3.23 (s, 6H, OCH₃). ¹³C NMR (CDCl₃, 63 Hz): δ 155.0, 119.2, 112.8, 104.6 (Ar-C, CN), 71.5, 70.6, 70.2, 70.1, 69.7, 69.0 (OCH₂), 58.6 (OCH₃). HRMS-ESI: m/z 453.2230 [M+H]⁺, calcd. for [C₂₂H₃₃N₂O₈]⁺ 453.2231. **3**, ¹H NMR (acetone-d₆, 250 MHz): δ 7.49 (d, J = 9.4 Hz, 1H, Ar-H), 7.36 (d, J = 9.4 Hz, 1H, Ar-H), 4.30 (t, J = 4.5 Hz, 2H, OCH₂), 3.84 (t, J = 4.5 Hz, 2H, OCH₂), 3.67–3.63 (m, 2H, OCH₂), 3.59–3.54 (m, 4H, OCH₂), 3.46–3.43 (m, 2H, OCH₂), 3.26 (s, 3H, OCH₃). ¹³C NMR (acetone-d₆, 63 MHz): δ 155.80, 155.75, 123.66, 121.65, 114.37, 114.28, 104.30, 102.42 (Ar-C, CN), 72.53, 71.46, 71.14, 70.96, 70.81, 70.07 (OCH₂), 58.70 (OCH₃). HRMS-ESI: m/z 305.1140 [M-H][−], 306.1169 [M][−], calcd. for [C₁₅H₁₇N₂O₅][−] 305.1142, [C₁₅H₁₈N₂O₅][−] 306.1216.
28. Selected spectroscopic data for ZnPcs: **4**, ¹H NMR (DMF-d₇, 400 MHz): δ 9.45 (br, 4H, Ar-H), 9.25 (d, 2H, J = 7.4 Hz, Ar-H), 8.95 (s, 2H, Ar-H), 8.21–8.17 (m, 6H, Ar-H), 7.31 (s, 2H, Ar-H), 7.25 (s, 2H, Ar-H), 4.38 (t, J = 4.3 Hz, 4H, OCH₂), 4.00 (t, J = 4.3 Hz, 4H, OCH₂), 3.77 (t, J = 4.5 Hz, 4H, OCH₂), 3.70 (t, J = 4.5 Hz, 4H, OCH₂), 3.66–3.55 (m, 4H, OCH₂), 3.59–3.56 (m, 4H, OCH₂), 1.59 (s, 18H, C(CH₃)₃), 1.40 (s, 18H, C(CH₃)₃). HRMS-ESI: m/z 1281.5361 [M+H]⁺, calcd. for [C₇₂H₈₁N₈O₁₀Zn]⁺ 1281.5362. UV-vis (DMSO): λ_{max} (log ε) 677 (5.0), 611 (4.2) nm. **5**, ¹H NMR (DMF-d₇, 400 MHz): δ 7.76 (d, J = 3.9 Hz, 8H, Ar-H), 4.97–4.91 (m, 32H, OCH₂), 4.15 (t, J = 4.9 Hz, 16H, OCH₂), 3.75 (t, J = 4.9 Hz, 16H, OCH₂), 3.58–3.56 (m, 16H, OCH₂), 3.36–3.34 (m, 16H, OCH₂), 3.16 (s, 24H, OCH₃). HRMS-ESI: m/z 965.9939 [M+K+Na-4H]^{2−}, calcd. for [C₈₈H₁₂₄N₈O₃₂ZnKNa]^{2−} 966.3582. UV-vis (DMSO): λ_{max} (log ε) 749 (5.0), 674 (4.5) nm. **6**, ¹H NMR (DMF-d₇, 400 MHz): δ 9.57–9.45 (m, 8H, Ar-H), 8.76–8.67 (m, 6H, Ar-H), 4.83 (br, 2H, OCH₂), 4.19 (br, 2H, OCH₂), 3.91–3.79 (m, 6H, OCH₂), 3.56 (br, 2H, OCH₂), 3.26 (s, 3H, OCH₃). MS (MALDI-TOF) m/z 723.6 [M-OCH₃]⁺, calcd. for [C₃₈H₂₇N₈O₄Zn]⁺ 723.1. UV-vis (DMSO): λ_{max} (log ε) 676 (3.6), 657 (3.3) nm.
29. Fukuda T, Homma S, Kobayashi N. Chem. Eur. J. 2005; 11:5205–5216. [PubMed: 15973747]
30. Maqanda W, Nyokongo T, Maree MD. J. Porphyrins Phthalocyanines. 2005; 9:343–351.
31. Li H, Fronczek FR, Vicente MGH. Tetrahedron Lett. 2008; 49:4828–4830.
32. Li HR, Fronczek FR, Vicente MGH. J. Organomet. Chem. 2009; 694:1607–1611. [PubMed: 20808725]
33. Russell, DA.; Cook, MJ. United States Patent. 5834455. 1998.
34. Phthalonitrile **3**: C₁₅H₁₈N₂O₅, M_r = 306.31, triclinic space group P-1, a = 8.9144(5), b = 10.9803(10), c = 15.9181(15) Å, α = 82.666(5), β = 89.322(5), γ = 87.909(5)°, V = 1544.3 (2) Å³, Z = 4, D_x = 1.317 g cm^{−3}, CuKα radiation, λ = 1.54178 Å, T = 90K, μ = 0.84 mm^{−1}, θ_{max} = 68.2°, colorless lath 0.30 × 0.14 × 0.07 mm, Bruker Kappa Apex-II CCD diffractometer, 17,507 measured reflections, 5487 independent, 4228 with $I > 2\sigma(I)$, R_{int} = 0.046, R = 0.044, wR(F²) = 0.123 for 406 refined parameters and 5487 data, CCDC 826729.
35. Mewis RE, Savoie H, Archibald SJ, Boyle RW. Photodiagnosis and Photodynamic Therapy. 2009; 6:200–206. [PubMed: 19932452]
36. Atilla D, Durmus M, Gurek AG, Ahsen V, Nyokong T. Dalton Trans. 2007:1235–1243. [PubMed: 17353956]
37. Modibane DK, Nyokong T. Polyhedron. 2009; 28:479–484.
38. Chauke V, Durmus M, Nyokong T. J. Photochem. Photobiol. A:Chem. 2007; 192:179–187.
39. Kobayashi N, Ogata H, Nonaka N, Luk'yanets EA. Chem. Eur. J. 2003; 9:5123–5134. [PubMed: 14562330]
40. Swarts JC, Langner EH, Krokeide-Hove N, Cook MJ. J. Mat. Chem. 2001; 11:434–443.
41. Cook MJ, Dunn AJ, Howe SD, Thomson AJ, Harrison KJ. J. Chem. Soc.-Perkin Trans. 1988; 1:2453–2458.

Figure 1. Molecular structure of the two independent molecules of phthalonitrile **3** (above), showing hydrogen bonding (below).

Figure 2. Absorption spectra of PEG-substituted Zn(II)-Pcs **4** (solid line), **5** (dash line) and **6** (dotted line) in DMSO at 2×10^{-6} M.

Scheme 1.
Synthesis of Pcs **4** – **6**.

Table 1

Spectroscopic properties of Pcs **4–6** in DMSO at room temperature; Abs: absorption; Em: emission; SS: Stokes' shift;

Pc	Abs (λ_{max} , nm)	Em ^a (λ_{max} , nm)	Φ_f ^b	SS (nm)
4	677	680	0.28	3
5	749	751	0.08	2
6	676	677	0.13	1

^a excitation at 615 or 675 nm;

^b calculated using Zn(II)-phthalocyanine as the standard.